Inhaled corticosteroids in stable copd

The review has been carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations. The PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency’s opinion. The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States.

Inhaled corticosteroids in stable copd

inhaled corticosteroids in stable copd

Media:

inhaled corticosteroids in stable copdinhaled corticosteroids in stable copdinhaled corticosteroids in stable copdinhaled corticosteroids in stable copdinhaled corticosteroids in stable copd